Chester County News and Community Website
NEWTOWN SQUARE, PA – ArriVent BioPharma, Inc. (Nasdaq: AVBP) presented final proof-of-concept results from its global Phase 1b FURTHER trial of firmonertinib, an oral targeted therapy for patients with non-small …
ArriVent Reports Promising Results for Firmonertinib in Lung Cancer Patients With Rare EGFR Mutations Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) reported a wider second-quarter loss as the company pressed forward with late-stage development of its lead cancer drug, firmonertinib, and advanced …
ArriVent BioPharma Posts Q2 Loss as Cancer Drug Pipeline Advances Toward Key Milestones Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced it expects topline data in early 2026 from its global Phase 3 FURVENT trial evaluating firmonertinib as a first-line treatment …
ArriVent BioPharma Eyes Early 2026 for Phase 3 Lung Cancer Drug Data Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has shared encouraging interim results from its Phase 1b FURTHER trial, which investigates firmonertinib as a first-line monotherapy for non-small cell …
ArriVent BioPharma Reports Promising Results from Phase 1b Trial for Firmonertinib in NSCLC Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced that it will host a virtual investor event on June 23, 2025, at 8:00 am ET. The event will focus …
ArriVent BioPharma to Host Investor Event on Groundbreaking Firmonertinib Program for EGFR Mutant NSCLC Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) reported its first-quarter 2025 financial results, accompanied by updates on its pipeline progress and corporate milestones. The company continues to prioritize …
ArriVent BioPharma Reports Q1 2025 Financial Results and Highlights Key Achievements Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced the appointment of Merdad Parsey, M.D., Ph.D., to its Board of Directors. A respected leader in global clinical development, …
ArriVent BioPharma Appoints Dr. Merdad Parsey to Board of Directors Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (NASDAQ: AVBP) announced its 2024 financial results, showcasing significant progress in clinical programs and pipeline expansion. The company highlighted substantial milestones achieved over …
ArriVent BioPharma Reports 2024 Financial Results and Key Achievements Read More NEWTOWN SQUARE, PA and SHANGHAI, CHINA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced an exclusive license agreement with Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) for global rights outside Greater …
ArriVent BioPharma Secures Global Rights to MRG007 in Strategic Deal with Lepu Biopharma Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced its financial results for the third quarter of 2024, alongside significant progress in its lead program for firmonertinib, a …
ArriVent BioPharma Reports Advancements and Q3 2024 Financial Results Read More